Anne Arundel Medical Center | Anne Arundel Research Institute

Research site

(Unclaimed)

Location

2001 Medical Parkway Belcher Pavilion Suite 203, Annapolis, Maryland, United States of America

Site insights

Top conditions

Top treatments

Paclitaxel

Carboplatin

Bevacizumab

Pembrolizumab

Docetaxel

Cisplatin

Crizotinib

Exemestane

Palbociclib

Temozolomide

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

9 of 117 total trials

A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies

This is a global, multicenter, open-label safety extension study. Participants receiving single-agent trastuzumab emtansine or trastuzumab emtansine...

Active, not recruiting

Neoplasm Metastasis

Drug: Trastuzumab

Drug: Pertuzumab

Locations recently updated

A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)

The purpose of the study is to compare Mezigdomide (CC-92480/BMS-986348) with carfilzomib and dexamethasone (MeziKD) against carfilzomib and dexameth...

Enrolling

Relapsed or Refractory Multiple Myeloma

Drug: Mezigdomide

Drug: Dexamethasone

A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

The purpose of this study is to learn about the safety and how effective the study medicine (PF-07220060) plus fulvestrant is compared to the study d...

Active, not recruiting

Advanced or Metastatic Breast Cancer

Drug: Everolimus

Drug: Fulvestrant

PALbociclib CoLlaborative Adjuvant Study (PALLAS)

This is a prospective, two arm, international, multicenter, randomized, open-label Phase III study evaluating the addition of 2 years of palbociclib...

Active, not recruiting

Breast Cancer

Drug: Standard Adjuvant Endocrine Therapy

Drug: Palbociclib

Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer (PATINA)

The primary objective of this study is to demonstrate that the combination of palbociclib with anti-HER2 therapy plus endocrine therapy is superior t...

Active, not recruiting

Estrogen Receptor Positive Breast Cancer

HER-2 Positive Breast Cancer

Drug: palbociclib

Drug: trastuzumab

SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors

The purpose of this study is to evaluate the efficacy and safety of combination of SKB264 and Pembrolizumab in patients with selected solid tumors in...

Enrolling

Solid Tumor

Drug: SKB264

Drug: Pembrolizumab

STAND - Study of the AGN1 LOEP SV Kit Compared to PMMA in Patients with Vertebral Compression Fractures

This is a multicenter, single-blinded, randomized controlled clinical trial evaluating the safety and efficacy of the AGN1 LOEP SV Kit for the treatm...

Enrolling

Compression Fracture

Vertebral Compression Fracture

Device: Control Group: PMMA bone cement

Device: Treatment Group: AGN1 LOEP SV Kit

T-DM1 and Tucatinib Compared with T-DM1 Alone in Preventing Relapses in People with High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in pa...

Enrolling

Anatomic Stage III Breast Cancer AJCC V8

Anatomic Stage IIIA Breast Cancer AJCC V8

Biological: Trastuzumab Emtansine

Other: Quality-of-Life Assessment

ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation

This study is conducted to see if ziltivekimab reduces the risk of having cardiovascular events (for example heart attack and stroke) in people with...

Enrolling

Chronic Kidney Disease

Inflammation

Drug: Placebo (Ziltivekimab B)

Drug: Placebo (Ziltivekimab C)